BioLineRx Forms Joint Venture With Hemispherian to Advance Cancer Therapy

Reuters
2025.11.24 12:00
portai
I'm PortAI, I can summarize articles.

BioLineRx Ltd. has formed a joint venture with Hemispherian AS to develop GLIX1, an oral small molecule targeting DNA damage response in glioblastoma and other cancers. A Phase 1/2a clinical trial is set to begin in Q1 2026. This collaboration expands BioLineRx's cancer treatment pipeline.

BioLineRx Ltd. has established a joint venture with Hemispherian AS to advance the development of GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other cancers. A Phase 1/2a clinical trial of GLIX1 is expected to commence in the first quarter of 2026. This collaboration expands BioLineRx’s development pipeline into additional high-need cancer indications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN31628) on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer